Sun Pharmaceutical Industries Ltd.

Sun Pharmaceuticals is eying to expand its footprint in specialty product segment in the US. The company garnered 50% of its consolidated revenue from US market and throughout the last year it has ramped up its focus on ophthalmology and dermatology segments.

Last September Sun Pharmaceuticals also acquired exclusive rights to Merck's skin ailment drug which is under trial.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.